Genomic sequencing seems to have come of age with Illumina as a substantial driver and beneficiary. During the third quarter, the company achieved astonishing revenue growth of 35% to $481 million over the same quarter last year.
Genomics England has dropped two-thirds of the candidates to provide variant annotation and clinical interpretation services to the 100,000 Genomes Project after reviewing the first round of responses.
Preimplantation genetic screening and diagnostics provider Reprogenetics is partnering with Illumina to use its next-generation sequencing tech in its analysis of embryos and infertility.
Illumina has teamed up with AB Sciex to add proteomic data analysis capabilities to its BaseSpace platform. As a result of the collaboration, Illumina is hosting four apps for processing, analyzing and visualizing proteomics mass spectrometry data on BaseSpace.
Global CRO Quintiles and gene sequencing magnate Illumina are scouting for some promising scientists, offering the use of their cash and technology to advance oncology research.
Illumina has laid the groundwork for increased use of next-generation sequencing in clinical research by striking a deal with Big Pharma, which could result in the company disrupting diagnostics using its dominance in NGS.
Pharma giants AstraZeneca, Johnson & Johnson and Sanofi have teamed up with gene sequencing pioneer Illumina to create a single test that screen patients for a wealth of cancer-related gene variants, allowing drugmakers to identify the ideal recipients of their oncology drugs.
Illumina has inked deals with three major Big Pharma companies with a goal of developing a universal gene-sequencing companion diagnostic test system focused on cancer.
Oxford Nanopore has raised a huge amount of money for a very tiny technology--about $302 million in total since it was founded in 2005. But despite an unclear commercial timeline for this private, U.K. company, investors have piled in again with £35 million ($59 million).
While early adopters of Illumina's $1,000 genome machine the HiSeq X Ten have been testing the system for months, researchers from less wealthy organizations have had no access to the technology. In a limited way that changed this week, when the Garvan Institute of Medical Research, DNAnexus and AllSeq teamed up to share data from a HiSeq X Ten.